Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.

Author
Abreu, Maria T
Rowbotham, David S
Danese, Silvio
Sandborn, William J
Miao, Ye
Zhang, Hongyan
Tikhonov, Ilia
Panaccione, Remo
Hisamatsu, Tadakazu
Scherl, Ellen J
Publication date
2022-08
Subject
Gastroenterology

Metadata
Show full item record
Abstract
Background and aims: The UNIFI long-term extension [LTE] study reports the efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of maintenance therapy.
Citation
J Crohns Colitis . 2022 Aug 30;16(8):1222-1234
Type
Article
Handle
http://hdl.handle.net/20.500.14200/1935
Additional Links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426670/
DOI
10.1093/ecco-jcc/jjac030
PMID
35239968
Journal
Journal of Crohn's and Colitis
Publisher
Oxford University Press
Collections